NDRA vs NOTV

ENDRA Life Sciences Inc. vs Inotiv, Inc. — Valuation Comparison 2026

NDRA

Diagnostics & Research
ENDRA Life Sciences Inc.
Quality
3.6
out of 10
Value Trap
39
LOW
Price
$5.52
Last close
Models
6/13
Active
VS

NOTV

Diagnostics & Research
Inotiv, Inc.
Quality
5.5
out of 10
Value Trap
29
LOW
Price
$0.28
Last close
Models
1/13
Active

Model-by-Model Comparison

ModelType NDRA Fair ValueNDRA Upside NOTV Fair ValueNOTV Upside
Bayesian DCF Intrinsic $1.48 -73.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.14 +303.6%
Dynamic NAV Asset-Based $9.42 +70.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NDRA vs NOTV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NDRA vs NOTV — Which Stock Is More Undervalued?

NOTV scores higher with a 5.5/10 quality rating vs NDRA's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ENDRA Life Sciences Inc. (NDRA) and Inotiv, Inc. (NOTV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NDRA currently trades at $5.52 with a QOC of 3.6/10, while NOTV trades at $0.28 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).